Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
30 Septembre 2024 - 12:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2024
Commission File No. 001-39621
OPTHEA LIMITED
(Translation of registrant’s name into English)
Level 4
650 Chapel Street
South Yarra, Victoria, 3141
Australia
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
|
|
|
OPTHEA LIMITED |
|
(Registrant) |
|
|
|
|
By: |
/s/ Frederic Guerard |
|
Name: |
Frederic Guerard |
|
Title: |
Chief Executive Officer |
Date: 09/30/2024
Exhibit 99.1
ASX, Nasdaq and Media Release
September 30, 2024
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
Melbourne, Australia, and Princeton, NJ, US, September 30, 2024 -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in a fireside chat and be available for one-on-one investor meetings at the UBS Virtual Ophthalmology Day 2024 being held on October 2, 2024.
UBS Virtual Ophthalmology Day 2024
Fireside chat: Wednesday, October 2, 2024, 4:00 PM EST
Presenter: Frederic Guerard, PharmD, CEO
Webcast link: https://kvgo.com/ubs/opthea-ltd-oct-2024
The webcast can also be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST,NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn
Authorized for release to ASX by Frederic Guerard, CEO
|
|
Investor Inquiries |
Join our email database to receive program updates: |
PJ Kelleher LifeSci Advisors LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430 7579 Media Inquiries Silvana Guerci-Lena NorthStream Global Partners silvana@nsgpllc.com |
Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com Source: Opthea Limited |
Opthea (PK) (USOTC:CKDXF)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Opthea (PK) (USOTC:CKDXF)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
